Monoclonal antibody therapy or Bamlanivimab is a great treatment option for non-hospitalized COVID positive patients. Lincoln Medical Center began offering the treatment to qualified patients in October 2020 with great success.
According to the FDA, which issued an emergency use authorization for the treatment in November, monoclonal antibodies are “laboratory-made proteins that mimic the immune system’s ability to fight off harmful antigens such as viruses.” Bamlanivimab specifically targets an immune response to the spike protein of SARS-CoV-2, which prevents the virus’ ability to attach to a human cell and reproduce.
Patients who qualify for monoclonal antibody therapy generally have a mild to moderate, confirmed case of COVID-19 with health factors placing them at risk for developing worse symptoms that could result in hospitalization.
The treatment is administered by intravenous (IV) infusion in a hospital setting and requires a physician’s order.
“The availability of this treatment here at Lincoln Medical Center is a wonderful tool that can be used to treat patients early preventing future hospitalizations,” said Lincoln Health System Chief Nursing Officer, Carrie Rogers.